Notice: This company has been marked as potentially delisted and may not be actively trading. Adagio Therapeutics (ADGI) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Adagio Therapeutics GAAP EPS of -$0.36 beats by $0.15November 9, 2023 | msn.comOur Favorite Advent CalendarsOctober 10, 2023 | nytimes.comAdagio Therapeutics GAAP EPS of -$0.46 misses by $0.11August 11, 2023 | msn.comDEADLINE TODAY: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the FirmApril 3, 2023 | benzinga.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses to Contact the FirmMarch 30, 2023 | markets.businessinsider.comFILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Invivyd, Inc. – IVVD, ADGIMarch 3, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGIFebruary 9, 2023 | benzinga.comForm 8.3 - Horizon Therapeutics PlcJanuary 25, 2023 | finance.yahoo.comInvivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA WorkshopDecember 19, 2022 | benzinga.comAdagio Therapeutics, now Invivyd, retools its strategy after losing two executivesOctober 17, 2022 | bizjournals.comAdagio Therapeutics, Inc.: Adagio Therapeutics Announces Corporate Name Change to InvivydSeptember 15, 2022 | finanznachrichten.deInvivyd Announces Multiple Next Generation COVID-19 AntibodySeptember 12, 2022 | tmcnet.comInvivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron VariantsSeptember 12, 2022 | finance.yahoo.comShort Interest in Adagio Therapeutics, Inc. (NASDAQ:ADGI) Drops By 13.2%August 31, 2022 | marketbeat.comHedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%August 22, 2022 | 247wallst.comAdagio Therapeutics (NASDAQ:ADGI) Shares Gap Up on Insider Buying ActivityAdagio Therapeutics (NASDAQ:ADGI) Shares Gap Up on Insider Buying ActivityAugust 22, 2022 | marketbeat.comMarc Elia Buys 584,451 Shares of Adagio Therapeutics, Inc. (NASDAQ:ADGI) StockAdagio Therapeutics, Inc. (NASDAQ:ADGI - Get Rating) Director Marc Elia acquired 584,451 shares of the business's stock in a transaction that occurred on Friday, August 19th. The shares were acquired at an average cost of $4.62 per share, with a total value of $2,700,163.62. Following the transaction, the director now directly owns 9,248,250 shares in the company, valued at approximately $42,726,915. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.August 19, 2022 | marketbeat.comQ3 2022 EPS Estimates for Adagio Therapeutics, Inc. (NASDAQ:ADGI) Decreased by Jefferies Financial GroupAdagio Therapeutics, Inc. (NASDAQ:ADGI - Get Rating) - Analysts at Jefferies Financial Group dropped their Q3 2022 earnings estimates for shares of Adagio Therapeutics in a report issued on Monday, August 15th. Jefferies Financial Group analyst M. Yee now expects that the company will post earninAugust 18, 2022 | marketbeat.comAdagio Therapeutics GAAP EPS of -$0.47August 17, 2022 | seekingalpha.comAdagio Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsAugust 15, 2022 | finance.yahoo.comAdagio Therapeutics, Inc. (NASDAQ:ADGI) Short Interest Up 7.9% in JulyAdagio Therapeutics, Inc. (NASDAQ:ADGI - Get Rating) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 4,230,000 shares, an increase of 7.9% from the July 15th total of 3,920,000 shares. Based on an average daily trading volume, of 813,200 shares, the days-to-cover ratio is presently 5.2 days. Approximately 10.7% of the company's shares are short sold.August 15, 2022 | marketbeat.comIs Adagio Therapeutics (NASDAQ:ADGI) In A Good Position To Invest In Growth?July 6, 2022 | finance.yahoo.comAdagio Elevates Interim Chief Executive David Hering To Permanent CEOJuly 5, 2022 | nasdaq.comMithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy CampaignJuly 5, 2022 | finance.yahoo.comAdagio Announces David Hering Named Permanent Chief Executive Officer and DirectorJuly 5, 2022 | finance.yahoo.com(ADGI) News: Did You Lose Money on Your Adagio Therapeutics Investment? Stock Price has Plummeted Since IPO - Contact Johnson FistelJuly 2, 2022 | benzinga.comAdagio Therapeutics (NASDAQ:ADGI) PT Lowered to $3.00 at Morgan StanleyMorgan Stanley reduced their price objective on Adagio Therapeutics to $3.00 and set an "underweight" rating on the stock in a research report on Tuesday.May 17, 2022 | marketbeat.comAdagio Therapeutics Reports Q1 Net Loss of $100.7M, Cash Position of $532.2MMay 13, 2022 | investing.comAdagio Therapeutics Reports First Quarter 2022 Financial ResultsMay 13, 2022 | finance.yahoo.comAdagio stock falls after pausing filing plans for COVID therapy with FDAApril 14, 2022 | seekingalpha.comAdagio Therapeutics Provides Update on Timing of Adintrevimab EUA RequestApril 14, 2022 | finance.yahoo.comWhen Will Adagio Therapeutics, Inc. (NASDAQ:ADGI) Breakeven?April 7, 2022 | finance.yahoo.comThe Petri Dish: Adagio says its antibody works against omicron nowMarch 31, 2022 | bizjournals.comPeering Into Adagio Therapeutics Inc. - Common Stock's Recent Short InterestMarch 30, 2022 | msn.comThiel-backed venture firm Mithril seeks to nominate candidates for Adagio's boardMarch 30, 2022 | nasdaq.comMid-Afternoon Market Update: Dow Drops 100 Points; Adagio Therapeutics Shares Spike HigherMarch 30, 2022 | markets.businessinsider.comAdagio's stock jumps as company says it will seek authorization for COVID-19 antibody treatmentMarch 30, 2022 | finance.yahoo.comAdagio Stock Spikes on New Data, but Its Omicron Problems RemainMarch 30, 2022 | finance.yahoo.comWHO urges countries to keep up COVID-19 testing and surveillance as the viral outbreak remains a global pandemicMarch 30, 2022 | finance.yahoo.comWhy Adagio Therapeutics Stock Is Soaring TodayMarch 30, 2022 | finance.yahoo.comWhy Is Adagio Therapeutics (ADGI) Stock Up Today?March 30, 2022 | investorplace.comAdagio stock soars 78% as COVID drug ADG20 meets main goals in trial; EUA filing in Q2March 30, 2022 | seekingalpha.comAdagio Therapeutics Says Its Investigational Drug For Covid-19 Met Primary EndpointsMarch 30, 2022 | nasdaq.comAdagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use AuthorizationMarch 30, 2022 | finance.yahoo.comAdagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer | MorningstarFebruary 26, 2022 | morningstar.comAdagio Therapeutics names David Hering as interim CEOFebruary 24, 2022 | seekingalpha.comAdagio Therapeutics Announces David Hering Appointed Interim Chief Executive OfficerFebruary 24, 2022 | finance.yahoo.comAdagio falls after announcing resignation of CEOFebruary 22, 2022 | seekingalpha.comAdagio Therapeutics Announces ADG20 Development Plans and Pipeline UpdatesFebruary 22, 2022 | finance.yahoo.comAdagio CEO Gerngross to exit Covid antibody company he foundedFebruary 22, 2022 | finance.yahoo.com Get Adagio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADGI and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Crash Ahead? (27 Experts Weigh In) (Ad)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you! Click here to reserve your spot at the emergency crypto summit now. ADGI Media Mentions By Week ADGI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADGI News Sentiment▼0.000.41▲Average Medical News Sentiment ADGI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADGI Articles This Week▼00▲ADGI Articles Average Week Get Adagio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADGI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Neumora Therapeutics News Today Recursion Pharmaceuticals News Today Beam Therapeutics News Today Tectonic Therapeutic News Today BioCryst Pharmaceuticals News Today Immunocore News Today Novavax News Today Tarsus Pharmaceuticals News Today Autolus Therapeutics News Today Vir Biotechnology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADGI) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
